LYON, France--(BUSINESS WIRE)--Regulatory News:
ERYTECH (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical need, will be presenting at Jefferies Global Healthcare Conference in London next week.
Gil Beyen, Chairman and CEO, will present on Thursday, November 20, 2014 at 12:20 p.m. GMT.
A live webcast will be accessible via the Investors page of the ERYTECH website at www.erytech.com. An archived replay of this webcast will be available on the Company's website for 30 days after the conference.
About ERYTECH and ERY-ASP/GRASPA®: www.erytech.com
Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.
By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA®, an innovative treatment that aims at destroying cancerous cells through “starvation” while significantly reducing side effects. ERY-ASP/GRASPA® has completed Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb in Acute Myeloid Leukemia (AML) in Europe. The product is also in Phase I/II in ALL in the U.S.
Every year about 50,000 patients are diagnosed with ALL or AML in Europe and the U.S. Today, approximately 80% of these patients, mainly adults, seniors and relapsed children, cannot use the current forms of asparaginase due to their toxicity. ERY-ASP/GRASPA® is being developed with the goal of improving the tolerability profile in order to treat all patients diagnosed with acute leukemia, even the most fragile ones. The market segment addressed by ERYTECH represents a potential of 1 billion euros.
ERYTECH is also developing treatments for solid tumors and some orphan indications outside oncology. It is currently conducting a Phase II study in pancreatic cancer in Europe and is examining other solid tumor indications for ERY-ASP.
The company has obtained orphan drug designations for ERY-ASP/GRASPA® in ALL, AML and pancreatic cancer in Europe and the U.S. It has its own operational manufacturing sites in Lyon, France and Philadelphia, U.S.
ERYTECH has concluded two distribution partnership agreements in the field of acute leukemia, one in Europe with Orphan Europe (Recordati Group), and the other in Israel with the TEVA Group.
ERYTECH is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker code: ERYP) and is part of the CAC All Shares, CAC Healthcare, CAC Pharma & Bio, CAC Small, CAC Mid&Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH shares are eligible to PEA-PME (French share savings plan for SMEs).